InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'

被引:2
作者
Schreij, Gerrit
Janknegt, Robert [1 ]
机构
[1] Maasland Ziekenhuis, Dept Clin Pharm, Sittard, Netherlands
[2] Maasland Ziekenhuis, Dept Toxicol, Sittard, Netherlands
[3] Univ Hosp Maastricht, Maastricht, Netherlands
关键词
AIDS; combivir; HIV; InforMatrix; NRTI-backbones; truvada;
D O I
10.1517/14656566.8.S1.S37
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
InforMatrix is an interactive decision matrix technique. This paper describes the use of InforMatrix to determine an order of merit within the various nucleoside and nucleotide reverse transcriptase inhibitors. In the order of merit, six criteria (effectiveness, safety, tolerance, convenience, usability and costs) are weighted against each other. Data necessary for this weighting process are derived from literature as well as personal practical experience. This article gives an overview of the most relevant information from clinical trials, cohort studies and databases concerning backbones consisting of two nucleoside/nucleotide reverse transcriptase inhibitors in the treatment of HIV infections, as well as a description of the interactive decision matrix technique. By using this interactive matrix technique, a rational consideration of the treatment options for backbones consisting of two nucleoside/nucleotide reverse transcriptase inhibitors becomes possible.
引用
收藏
页码:S37 / S47
页数:11
相关论文
共 68 条
[1]   Clinical pharmacokinetics of zidovudine - An update [J].
Acosta, EP ;
Page, LM ;
Fletcher, CV .
CLINICAL PHARMACOKINETICS, 1996, 30 (04) :251-262
[2]   Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].
Alberti, A ;
Clumeck, N ;
Collins, S ;
Gerlich, W ;
Lundgren, J ;
Palù, G ;
Reiss, P ;
Thiebaut, R ;
Weiland, O ;
Yazdanpanah, Y ;
Zeuzem, S .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624
[3]   Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2 [J].
Amin, J ;
Moore, A ;
Carr, A ;
French, MA ;
Law, M ;
Emery, S ;
Cooper, DA .
HIV CLINICAL TRIALS, 2003, 4 (04) :252-261
[4]   Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature [J].
Ammassari, A ;
Trotta, MP ;
Murri, R ;
Castelli, F ;
Narciso, P ;
Noto, P ;
Vecchiet, J ;
D'Arminio Monforte, A ;
Wu, AW ;
Antinori, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S123-S127
[5]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[6]   Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort [J].
Barret, B ;
Tardieu, M ;
Rustin, P ;
Lacroix, C ;
Chabrol, B ;
Desguerre, I ;
Dollfus, C ;
Mayaux, MJ ;
Blanche, S .
AIDS, 2003, 17 (12) :1769-1785
[7]   An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults [J].
Bartlett, John A. ;
Fath, Michael J. ;
DeMasi, Ralph ;
Hermes, Ashwaq ;
Quinn, Joseph ;
Mondou, Elsa ;
Rousseau, Franck .
AIDS, 2006, 20 (16) :2051-2064
[8]   InforMatrix as an alternative tool in rational and transparent drug-decision making [J].
Brenninkmeijer, Rob ;
Mairs, Jill ;
Timoney, Mark ;
Scott, Mike ;
McElnay, James ;
Janknegt, Robert .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 :S31-S36
[9]   A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study [J].
Carr, A ;
Chuah, J ;
Hudson, J ;
French, M ;
Hoy, J ;
Law, M ;
Sayer, D ;
Emery, S ;
Cooper, DA .
AIDS, 2000, 14 (09) :1171-1180
[10]   A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients [J].
Carr, A ;
Vella, S ;
deJong, MD ;
Sorice, F ;
Imrie, A ;
Boucher, CA ;
Cooper, DA .
AIDS, 1996, 10 (06) :635-641